![]() |
市場調查報告書
商品編碼
1309231
紅色生物技術市場 - 2018-2028 年全球產業規模、佔有率、趨勢、競爭、機會和預測,按產品類型、應用、最終用戶和地區分類Red Biotechnology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Application, By End-User, By Region |
在2024-2028 年的預測期內,全球紅色生物技術市場預計將以驚人的複合年成長率成長。這主要歸因於對基因工程的需求不斷成長、用於治療危及生命的疾病的新藥開發以及精準醫療產量的增加等因素。
由於生物藥物的增加,對基因工程的需求也在增加。根據IQVIA 研究所的數據,生物藥占美國所有處方藥的2%,但卻佔藥品支出淨額的37%。基因工程(如重組DNA 技術)在製造基因改造生物(如治療性抗體)中的應用日益廣泛,推動了全球紅色生物技術市場的成長。基因編輯(如基於CRISPR 的基因編輯)等技術在市場上也越來越普遍,從而通過擴大紅色生物技術在基因工程中的應用支持了市場的成長。此外,通過組織工程技術,紅色生物技術還可應用於生產椎間盤、人造骨骼、皮膚和軟骨。
紅色生物技術可應用於基因治療、臨床試驗、診斷和研究等領域。此外,為開發藥物而進行的臨床試驗數量不斷增加,以及對生物學名藥的接受度和需求的上升,也影響了紅色生物技術近期的發展。隨著藥品生產中臨床試驗的不斷增加,預計紅色生物技術市場的生物製藥領域將不斷擴大。例如,2022 年7 月,Replay - 一家基因組藥物生產初創公司在種子輪融資中投資了5500 萬美元,通過開發各種基因型基因組研究的相互聯繫階段來發展和改造基因組醫學,從而發現新的疾病靶點,加強和改善疾病的診斷和治療。
全球慢性病發病率不斷上升,對精準醫療的需求也在不斷增加。據世界衛生組織(WHO)統計,癌症是全球第二大死因,全球約有960 萬人死於癌症。隨著全球癌症患者人數的不斷增加,紅色生物技術市場的成長也在不斷擴大,因為它可通過基因檢測和測序技術等用於診斷這些疾病的原因,從而在癌症等疾病的診斷、藥物開發和治療方面發現了許多有利可圖的機會,因此預計在預測期內將促進市場成長。此外,紅色生物技術還被用於聯合疫苗的生產,如乙型肝炎疫苗與脊髓灰質炎疫苗的合併,以及白百破疫苗與甲型肝炎疫苗的合併,這些都對支持預測期內的市場成長具有重要意義。
2022 年6 月,Bluebird Bio 開發出一種新型基因療法,該療法正在接受美國食品藥品管理局的評估,用於治療青少年患者的腦腎上腺白質營養不良症(CALD)(一種損害腦膜髓鞘的遺傳疾病)。
TechSci Research 可根據給定的市場數據,為公司的特定需求提供客製化服務。報告可提供以下客製化選項:
Global Red Biotechnology Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as the growing demand for genetic engineering, the development of new medicines for the treatment of life-threatening diseases, and the increased production of precision medicine.
Red Biotechnology focuses on the therapeutic or diagnostic use of living cells and their components to develop novel medical treatments and cures for diseases and health issues. It includes the creation of a wide range of goods, including medicines, diagnostic instruments, vaccines, gene treatments, and other products for the treatment and prevention of different diseases.
The growing demand for precision medicine is enhancing the market opportunities and increasing demand for the global red biotechnology market.
An increase in demand for genetic engineering has been observed due to an increase in biologic drugs. According to IQVIA Institute data, biologic drugs represented 2 percent of all United States prescriptions but comprised 37% net drug spending. The growing use of genetic engineering, such as recombinant DNA technology, in creating genetically modified organisms, such as therapeutic antibodies, is propelling the growth of the red biotechnology market across the globe. The technologies, such as gene editing, such as CRISPR-based genetic editing, are also becoming much prevalent in the market and thereby are supporting the market growth by expanding the applications of red biotechnology in genetic engineering. Additionally, red biotechnology is found to have applications in the production of spinal discs, artificial bones, skin, and cartilage through tissue engineering techniques.
Red biotechnology has found applications in fields such as gene therapy, clinical trials, diagnostics, and research. Also, the growing number of clinical trials for the development of drugs, along with the rise in acceptance and demand for biosimilars, affect the growth of red biotechnology in the recent scenario. The expansion of the biopharmaceutical sector of the red biotechnology market is expected to grow with increasing clinical trials in medicine production. For instance, In July 2022, Replay-a genomic medicine-producing startup, invested USD55 million in a seed funding round to develop and transform genomic medicine through an interlinking stage for developing various genotype genomic research to discover new disease targets and enhance and improve the disease diagnosis & treatment.
The growing prevalence of chronic diseases across the world is creating a rising demand for precision medicine. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and has recorded around 9.6 million deaths globally. With the increasing number of cancer patients worldwide, the growth of the red biotechnology market is also expanding as it is utilized for diagnosing the reason for these diseases by using genetic testing and sequencing techniques, etc., and thereby has found many lucrative opportunities in diagnosis, drug development and treatment for diseases such as cancer and is thereby expected to bolster market growth in the forecast period. Along with this, red biotechnology is utilized in combined vaccine production, such as Hepatitis B, merged with the polio vaccine, and DPT merged with Hepatitis A, and this all together is of great importance to support the market growth in the forecast period.
In June 2022, Bluebird Bio developed a new gene therapy that is being evaluated by the United States Food Drug and Administration regarding the treatment of (CALD) cerebral adrenoleukodystrophy (a genetic condition that damages the membrane myelin sheath of the brain) in patients under adolescent age.
Global Red Biotechnology Market is segmented based on the product type, application, end-user, region, and competitive landscape. Based on product type, the market is segmented into diagnostic reagents, human vaccines, blood products, gene recombinant drugs, and others. Based on application, the market is segmented into biopharmaceutical production, gene therapy, genetic testing, pharmacogenomics, drug discovery, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, CMO & CRO, research institutes, and others.
Pfizer, Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche, Ltd., Bruker, Merck KGaA, Celgene Corporation, Amgen, Inc., etc., are some of the major players operating in the Global Red Biotechnology Market.
In this report, Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Red Biotechnology Market.
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: